Cargando…

Case Report: Long-Acting Oral Cariprazine

INTRODUCTION: Cariprazine is a third-generation antipsychotic, approved for the treatment of schizophrenia and bipolar disorder and used off-label for schizoaffective disorder and treatment-resistant depression. Cariprazine is a partial agonist at dopamine receptors D2 and D3 and serotonin receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dyrmishi, Emanuela, De Pieri, Marco, Ferrari, Marco, Traber, Rafael, Preve, Matteo, De Peri, Luca, Bolla, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093047/ https://www.ncbi.nlm.nih.gov/pubmed/35573352 http://dx.doi.org/10.3389/fpsyt.2022.876003

Ejemplares similares

Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder
por: De Pieri, M., et al.
Publicado: (2022)

Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
por: De Pieri, Marco, et al.
Publicado: (2023)

Cariprazine Use in Early Psychosis: Three Case Reports
por: Coentre, Ricardo, et al.
Publicado: (2021)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine
por: Moran, Robert A, et al.
Publicado: (2023)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series
por: Vannucchi, Tommaso, et al.
Publicado: (2022)

Case report: Treatment-resistant schizophrenia with auto-aggressive compulsive behavior—Successful management with cariprazine
por: Renemane, Lubova, et al.
Publicado: (2023)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
por: Palacios-Garrán, Roberto, et al.
Publicado: (2022)

Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report
por: Sahlsten Schölin, Johan, et al.
Publicado: (2023)

Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
por: Csehi, Réka, et al.
Publicado: (2022)

Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery
por: Taube, Maris
Publicado: (2021)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
por: Vrublevska, Jelena
Publicado: (2023)

Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder
por: Bogren, Mats, et al.
Publicado: (2022)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up
por: Pappa, Sofia, et al.
Publicado: (2023)

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting
por: Galmes, Lluis Niell, et al.
Publicado: (2023)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Cariprazine pharmacokinetics
Publicado: (2022)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
por: Ventriglio, Antonio, et al.
Publicado: (2019)

The gordian knot of overlapping symptoms between dissociative identity disorder and borderline personality disorder, the need for a clear cut: A case report
por: Romanos, I., et al.
Publicado: (2021)

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
por: Berardis, Domenico De, et al.
Publicado: (2021)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
por: Ivanov, Stanislav V., et al.
Publicado: (2022)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Editorial: Trajectories of Brain Abnormalities in Early Schizophrenia
por: Vita, Antonio, et al.
Publicado: (2021)

Cariprazine treatment in patients with psychosis related to Parkinson’s Disease: a case report.
por: Martín De Argila Lorente, M., et al.
Publicado: (2023)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report
por: Wang, Feng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bo0gob25l9432vnvvni70vj9uk